Business, energy, technology, markets and global industry news from Business News Today

RNA editing

PharmaDeviceNews RNA editing
Representative image: Advanced liver cancer imaging and RNA-based oncology research illustrate Rznomics Inc.’s FDA RMAT designation for RZ-001 in hepatocellular carcinoma, highlighting the growing role of RNA editing in next-generation cancer therapy.
Pharma & Biotech

FDA RMAT status puts Rznomics’ RNA editing platform under a brighter clinical spotlight

RNA editing just gained a liver cancer spotlight. Rznomics must now prove RZ-001 can turn early response signals into durable clinical value.

Read More
Pharma & Biotech

Can Rznomics turn RZ-001 into a breakthrough therapy for hepatocellular carcinoma?

Rznomics reported interim RZ-001 liver cancer data at AACR 2026. Read why the efficacy and safety signals could matter for hepatocellular carcinoma.

Read More